Puma Biotechnology, Inc. (PBYI) |
| 7.05 -0.07 (-0.98%) 11-20 16:00 |
| Open: | 7.05 |
| High: | 7.22 |
| Low: | 6.91 |
| Volume: | 861,208 |
| Market Cap: | 364(M) |
| PE Ratio: | 11.56 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 11.50 |
| Resistance 1: | 9.75 |
| Pivot price: | 8.36 |
| Support 1: | 6.91 |
| Support 2: | 5.75 |
| 52w High: | 11.5 |
| 52w Low: | 4.84 |
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
| EPS | 0.460 |
| Book Value | 2.590 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.305 |
| Profit Margin (%) | 10.27 |
| Operating Margin (%) | 9.62 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 12 Nov 2026
A director proposes selling 15,000 Puma Biotechnology (PBYI) shares. - Stock Titan
Tue, 10 Nov 2026
Puma Biotechnology, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-11-10 - Seeking Alpha
Thu, 29 Oct 2026
Puma Biotechnology, Inc. (PBYI) Seasonal returns chart - Yahoo Finance UK
Wed, 12 Aug 2026
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance
Thu, 11 Jun 2026
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
Wed, 27 May 2026
PBYI - Puma Biotechnology Inc Stock Price and Quote - Finviz
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |